




# PHARMACEUTICAL 2019

Blueprint Medicines Corp  
Rank 129 of 363





RealRate

# PHARMACEUTICAL 2019

## Blueprint Medicines Corp Rank 129 of 363



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Blueprint Medicines Corp is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 146%, being 110% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	499,787
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,323
Liabilities, Non-Current	42,759
Other Assets	10,710
Other Compr. Net Income	89
Other Expenses	0
Other Liabilities	18,033
Other Net Income	10,386
Other Revenues	44,521
Property and Equipment	29,627
Research and Development	243,621
Selling, General and Administrative Expense	47,928

Output Variable	Value in 1000 USD
Assets	540,124
Liabilities	121,115
Expenses	291,549
Revenues	44,521
Stockholders Equity	419,009
Net Income	-236,642
Comprehensive Net Income	-236,598
Economic Capital Ratio	146%